GenVec, Inc. - Securities Class Action

Company and Case Information

IMPORTANT INFORMATION | INDEX OF FILINGS | SEARCH

Home

Index of Filings

News and Press Releases

Filings

Decisions

Settlements

Litigation Activity Indices

Top Ten List

Annual/Quarterly Updates

Clearinghouse Research

Articles & Papers

Search

Related Sites

About Us

Local Rules

Sponsors

Register

_______________
Copyright (c) 2001
Stanford Law School

GenVec, Inc. Summary: According to the lawsuit that has been filed against GenVec and certain of its officers for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 was on behalf of all investors who purchased or otherwise acquired GenVec, Inc. (NASDAQ: GNVC) common stock between March 12, 2009 and March 30, 2010, inclusive ("Class Period").

GenVec is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. The complaint alleges that throughout the Class Period, GenVec and its most senior officers continuously touted the clinical success of TNFerade, and that it was the company's lead product candidate with strategic commercial value.

However, the complaint alleges, investors began to learn on March 29, 2010 that those statements were knowingly false and misleading when GenVec announced that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer. On this news, the Company's stock price declined $20.10 per share -- from $28.10 per share on March 29, 2010 to close at $8.00 per share on March 30, 2010 -- a decline of more than 71.5% on unusually high volume.

INDUSTRY CLASSIFICATION:
SIC Code: 2834
Sector: Healthcare
Industry: Biotechnology & Drugs

COMPANY/ISSUER NAME:	GenVec, Inc.
COMPANY/ISSUER TICKER:	GNVC
COMPANY WEBSITE:	http://www.genvec.com

FIRST IDENTIFIED COMPLAINT IN THE DATABASE

Satish Shah, et al. v. GenVec, Inc., et al.

COURT: D. Maryland	DOCKET NUMBER: 12-CV-00341
JUDGE NAME:
DATE FILED: 02/03/2012	SOURCE:
CLASS PERIOD START: 03/12/2009	CLASS PERIOD END: 03/30/2010
TYPE OF COMPLAINT: Complaint (Unamended and Unconsolidated)
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Brower Piven (Stevenson) 1925 Old Valley Road, Stevenson, MD, 21153 (voice) (410) 332-0030, (fax) (410) 685-1300, piven@abrowerpiven.com _____________________________________________ TOTAL NUMBER OF PLAINTIFF FIRMS: 1

DOCUMENTS FOR THE FIRST IDENTIFIED COMPLAINT
Class Action Complaint for Violation of Federal Securities Laws
Type: Complaint		Date on the document: 02/03/2012
U.S. District Court Civil Docket
Type: Other		Date on the document: 02/06/2012

OTHER DOCUMENTS

Case Name and/or Number:
Type:		Date on the document:

WARNING AND DISCLAIMER OF LIABILITY:
The information included on this Web site, whether provided by personnel employed by Stanford Law School or by third parties, is provided for research and teaching purposes only. Neither Stanford University, Stanford Law School, nor any of their employees, agents, contractors, or affiliates warrant the accuracy or completeness of the information or analyses displayed herein, and we caution all readers that inclusion of any information on this site does not constitute an endorsement of the truthfulness or accuracy of that information. In particular, this Web site contains complaints and other documents filed in federal and state courts, which make allegations that may or may not be accurate. No reader should, on the basis of information contained in or referenced by this Web site, assume that any of these allegations are truthful.

Go to Search page | Go to Case Index page | Back to Top

�